Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 42, Issue 8 (Aug 2004)


Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity

Nikoleta Ziouti / Demitrios H. Vynios / Alexios J. Aletras / Dora Kyriakopoulou / Anna Mastorakou / Andreas Andonopoulos
  • Rheumatology Clinic, University Hospital and Department of Medical Sciences, University of Patras, Patras, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2004.143


Matrix metalloproteinases participate in the degradation of the extracellular matrix proteins and are regulated mainly by their respective tissue inhibitors. In a variety of inflammatory connective tissue diseases, variations in the tissue content of both metalloproteinases and tissue inhibitors have been reported. The purpose of this study was to determine the serum levels of metalloproteinases and tissue inhibitors in patients with autoimmune diseases and compare with those of healthy individuals of similar age. The metalloproteinase content was analyzed by zymography and it was found that the serum levels of metalloproteinase-2 and metalloproteinase-9 of all autoimmune disease samples were decreased, in all diseases examined and independently of clinical activity, while those of active metalloproteinase-9 were significantly elevated. Both tissue inhibitors were quantitated by direct enzyme-linked immunosorbent assay and were also found decreased in autoimmune disease samples, confirming the balance that should exist in the secretion of metalloproteinases and tissue inhibitors. These results suggested that the increased active form of metalloproteinase-9, together with the decreased concentration of tissue inhibitor-2, could be used for diagnostic purposes and for the follow-up of patients with autoimmune diseases.

Keywords: ageing; enzymes; osteoarthritis; rheumatoid arthritis


  • 1

    Gartaganis SP, Georgakopoulos CD, Mela EK, Exarchou A, Ziouti N, Assouti M, et al. Matrix metalloproteinases and their inhibitors in exfoliation syndrome. Opthalmic Res 2002; 34:165–71.Google Scholar

  • 2

    Preston A. Extracellular Matrix Proteases & Proteins Technical Guide. Calbiochem® and Oncogene™ Research Products, 2002.Google Scholar

  • 3

    Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127:393–8.Google Scholar

  • 4

    Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001; 125:340–4.Google Scholar

  • 5

    Syggelos SA, Eleftheriou SC, Giannopoulou E, Panagiotopoulos E, Aletras A. Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses. J Rheumatol 2001; 28:1319–29.Google Scholar

  • 6

    Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004; 10:1057–63.CrossrefGoogle Scholar

  • 7

    Deutscher MP. One-dimensional gel electrophoresis. In: Deutscher MP, editor. Methods in enzymology. San Diego, CA: Academic Press, 1990;182:425pp.Google Scholar

  • 8

    Patron CF, Zouki C, Whittal RM, Chan JSD, Davidge ST, Filep JG. Methods for analysis of matrix metalloproteinase regulation of neutrophil-endothelial cell adhesion. Biol Proced Online 2002; 4:38–48.Google Scholar

  • 9

    Ziouti N, Triantaphyllidou IE, Assouti M, Papageorgakopoulou N, Kyriakopoulou D, Anagnostides ST, et al. Solid phase assays in extracellular glycoconjugate research. J Pharm Biomed Anal 2004; 34:771–89.Google Scholar

  • 10

    Murphy G, Koklitis P, Carne AF. Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. Biochem J 1989; 261:1031–4.Google Scholar

  • 11

    Ribbens C. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002; 61:161–6.Google Scholar

  • 12

    Zucker S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999; 878:212–27.Google Scholar

  • 13

    Avolio C, Ruggieri M, Giulani F, Liuzzi GM, Leante R, Riccio P, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136:46–53.Google Scholar

  • 14

    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 2002; 41:78–87.Google Scholar

  • 15

    Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996; 78:161–71.Google Scholar

  • 16

    Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 6:473–88.CrossrefGoogle Scholar

  • 17

    Yoshihara Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59:455–61.Google Scholar

  • 18

    Perez P. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 2000; 43:2807–17.Google Scholar

  • 19

    Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003; 70:373–8.Google Scholar

  • 20

    Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel A, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002; 13:1550–7.CrossrefGoogle Scholar

  • 21

    Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003; 49:339–40.Google Scholar

  • 22

    Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314:241–4.Google Scholar

  • 23

    Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 (MMP-9) in human plasma. Anal Biochem 2003; 322:283–6.Google Scholar

  • 24

    Makowskia GS, Ramsby ML. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta 2003; 329:77–81.Google Scholar

  • 25

    Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002; 20:221–4.Google Scholar

About the article

Corresponding author: Demitrios H. Vynios, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece. Phone: +30-2610-997876, Fax: +30-2610-997154, E-mail:

Received: 2004-03-08

Accepted: 2004-05-10

Published Online: 2005-06-01

Published in Print: 2004-08-01

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.143.

Export Citation

© Walter de Gruyter. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

G. Schmalz, I. Davarpanah, J. Jäger, R.F. Mausberg, B. Krohn-Grimberghe, J. Schmidt, R. Haak, U. Sack, and Dirk Ziebolz
Journal of Microbiology, Immunology and Infection, 2017
N. Ziouti, N.S. Mastronikolis, A.P. Andonopoulos, C.D. Georgakopoulos, and D.H. Vynios
Analytical Biochemistry, 2006, Volume 350, Number 1, Page 159
Chris C. Woods, Krishnan Sundar, Cynthia Tessler, Ty W. Lebsack, Lora Grainger, Alma Nielsen, David Bleich, and Dominick DeLuca
Journal of Autoimmunity, 2006, Volume 27, Number 1, Page 28

Comments (0)

Please log in or register to comment.
Log in